Imbalances in the composition of BCL2 family proteins contribute to tumourigenesis and therapy resistance of mantle cell lymphoma (MCL), making these proteins attractive therapy targets. We studied the efficiency of dual targeting the NOXA/ MCL1 axis by combining fatty acid synthase inhibitors (NOXA stabilization) with the CDK inhibitor Dinaciclib (MCL1 reduction). This combination synergistically induced apoptosis in cell lines and primary MCL cells and led to almost complete inhibition of tumour progression in a mouse model. Apoptosis was NOXA-dependent and correlated with the NOXA/MCL1 ratio, highlighting the importance of the NOXA/MCL1 balance for effective cell death induction in MCL.
Mantle cell lymphoma (MCL) is a rare lymphoid neoplasm characterized by an abnormal proliferation of mature B-lymphocytes derived from the mantle zone of lymphoid follicles. Although high initial response rates can be achieved with current standard therapy, most patients suffer early relapses and rapid disease progression (Dreyling & Ferrero, 2016) . Recently, new innovative drugs with promising clinical activity, such as bortezomib, temsirolimus, lenalidomide and ibrutinib have been approved in MCL (Dreyling & Ferrero, 2016) , but a curative therapy has to be established. Therefore, further investigation of molecular pathogenesis and identification of crucial oncogenic signalling pathways underlying the aggressiveness and chemorefractiveness of the disease are still highly warranted. The interplay between proand anti-apoptotic proteins of the BCL2 family is crucial in regulating mitochondrial apoptosis and imbalances in the composition of these proteins contribute to tumourigenesis and therapy resistance (Elkholi et al, 2011) , making these proteins attractive targets. Preclinical studies and initial clinical trials on the BH3 mimetics Navitoclax and Venetoclax in chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma have revealed promising results. Importantly, these compounds are specific for BCL2 and/or BCL-XL (BCL2L1)/BCL-w (BCL2L2) but inactive against the antiapoptotic MCL1 protein (Vela & Marzo, 2015) . The balance between MCL1 and its predominant binding partner, the BH3-only protein NOXA (also termed PMAIP1), is not only predictive for sensitivity to these BH3 mimetics but also plays a general role in fine-tuning life/death decisions upon chemotherapy, in normal physiology and in tumour development (Ploner et al, 2008) . Importantly, MCL cells are characterized by a short half-life of NOXA due to exceptionally low protein stability (Dengler et al, 2014) and modulation of NOXA protein expression has been described as the major mechanism to induce mitochondrial apoptosis upon treatment with proteasome inhibitors, such as bortezomib (P erez-Gal an et al, 2007) . Recently, Orlistat, a US Food and Drug Administration-approved lipase inhibitor and an effective fatty acid synthase inhibitor (FASNi), has also been described as a potent inducer of NOXA leading to apoptosis in MCL (Dengler et al, 2014) . Orlistat has been used in preclinical investigations against several cancer types with promising anti-tumour effects. Low bioavailability through enteric delivery and its hydrophobic nature present barriers to clinical use of Orlistat, but novel formulations such as amphiphilic bio-conjugates are currently under investigation leading to significantly improved anti-tumour efficacy (Hill et al, 2016) . Interestingly, in contrast to bortezomib, FASNis (e.g., Orlistat) interfere with the ubiquitination process of NOXA protein, thereby offering new strategies to kill bortezomib-resistant MCL cells (Dengler et al, 2014) . It is expected that expression levels of the anti-apoptotic MCL1 are important in determining sensitivity to NOXA-stabilizing agents. We therefore investigated if selected downregulation of MCL1 might provide an attractive avenue to potentiate the apoptotic effect of Orlistat, used here as a reference substance for NOXA stabilizing compounds.
Material and methods
Full experimental details are provided in the Supporting Information (Data S1 and Table SI) .
Cell lines, patient samples, and animals MINO, JEKO1 and JVM-2 were recently authenticated by short tandem repeat profiling and tested for mycoplasma contamination. Primary cells were obtained from peripheral blood of MCL patients diagnosed according to World Health Organization criteria (see Table SI for biological characteristics). All patients signed an informed consent according to the Declaration of Helsinki. Cultivation was performed as described in Data S1. Six-week-old CB17-severe combined immunodeficient female mice were inoculated subcutaneously with JEKO1 cells according to a protocol approved by the animal testing ethical committee of the University of Barcelona.
Statistical analysis
Data are represented as the mean AE SD of at least three independent experiments. All statistical analyses were done with GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Comparison between two groups of samples were analysed using two-sided t-test or nonparametric Wilcoxon test. Results were considered statistically significant when P < 0Á05.
Results and discussion
The present study showed that not only NOXA but also MCL1 was significantly up-regulated, even at sub-lethal doses of Orlistat (Fig 1A) , indicating that this upregulation might limit the efficacy of Orlistat-mediated NOXA-dependent apoptosis. This is supported by our finding that specific knockdown of MCL1 via siRNA leads to effective induction of apoptosis, even at the lowest used concentration of Orlistat ( Fig 1B) . Together, these results indicate that dual targeting of NOXA and MCL1 could be a promising strategy to enhance effectiveness of cell death induction in MCL.
MCL1 is characterized by a relatively short half-life and such proteins can selectively be reduced following CDK9 inhibition (Baker et al, 2016) . The broad-spectrum CDK inhibitor Dinaciclib was shown to effectively suppress MCL1 protein expression and to have antitumour activity in a variety of haematological malignancies, most probably due to transcriptional repression as a result of dephosphorylation of the RNA Pol II subunit RPB1 (P-RPB1) mediated by CDK9 inhibition (Bose et al, 2013) . Thus, we chose to investigate the potency of Dinaciclib as an efficient MCL1-inhibitor in MCL and to enhance the efficacy of cell death induction upon treatment with Orlistat. Dinaciclib induced a dosedependent cell death in MCL cell lines, with a 50% inhibitory concentration (IC 50 ) of 9-11 nmol/l ( Fig S1, Table SII ), similar to the doses reported in diffuse large B cell lymphoma (Gregory et al, 2015) . Of note, this cytotoxic effect was superior to that of the CDK inhibitor SNS-032 in this model (Chen et al, 2010) . Inhibition of CDK9 by Dinaciclib also resulted in rapid dephosphorylation of RPB1 and subsequent induction of a rapid and dose-dependent decrease of MCL1 protein level (Fig 1C) . Interestingly, slight downregulation of NOXA was also observed at higher doses of Dinaciclib (Fig 1C) , strengthening the hypothesis that combinatory treatment with NOXA inducers might be promising.
To evaluate the impact of a dual targeting approach of NOXA and MCL1, we combined Orlistat with Dinaciclib in the MCL cell lines MINO, JEKO1 and JVM-2, and in a Bortezomib resistant JEKO1 clone. Addition of Dinaciclib to Orlistat selectively prevented MCL1 upregulation, shifting the NOXA/MCL1 ratio towards NOXA, whereas BCL2, BCL-XL and PUMA (also termed BBC3) were not changed significantly (Figs 2A, S2, upper panels and S3). This was accompanied by a decrease in the number of viable cells as compared to single agent treatment in all cell lines investigated, irrespective of their sensitivity to bortezomib (Figs 2A; S2, lower panels and S4). Suppression of NOXA by siRNA prior to treatment with Dinaciclib and Orlistat partially prevented accumulation of NOXA and rescued the cells from apoptosis (Fig S5) , confirming that induction of cell death is dependent on the NOXA/MCL1 ratio. At apoptosis levels >30% (JEKO1) or >70% (MINO) Orlistat + Dinaciclib were significantly synergistic (cumulative incidence <1; Fig S6) . Synergistic (JEKO1) or additive effects (MINO) were also found for Cerulenin targeting the FASN ketoacyl synthase domain (Fig S7) . Interestingly, with Cerulenin, accumulation of NOXA was less pronounced when compared to Orlistat. However, induction of MCL1 was lacking, leading to a shift of the NOXA/MCL1 ratio towards NOXA upon addition of Dinaciclib (Fig S8) . Of note, despite comparable ratios of NOXA and MCL1 (Fig S9A) , combination of Dinaciclib with Bortezomib was, at most, additive and, at higher bortezomib concentrations, even antagonistic (Fig S9B) . This might be caused by a Bortezomib-mediated accumulation of a faster migrating MCL1 cleavage product (Fig S9C) which has been reported to be pro-apoptotic upon Bortezomib (Podar et al, 2008) . Importantly, this fragment was absent upon Orlistat treatment alone or in combination with Dinaciclib ( Fig S9C) .
Interestingly, primary MCL cells showed a significant response to low doses of Dinaciclib alone (Fig 2B) , indicating its potential use as monotherapy for MCL when compared to CLL primary samples, where minimal IC 50 doses of 130 nmol/l have been described (Sylvan et al, 2016) and promising clinical effects have been reported (Flynn et al, 2015) . Nonetheless, in six out of seven cases of our cohort, the combination of Dinaciclib with Orlistat was significantly more effective than either monotherapy (Fig 2B, upper  panel) . Similar to the results obtained in MCL cell lines, we observed NOXA protein accumulation and concomitant MCL1 downregulation upon the combination treatment (Fig 2B, lower panel) . Finally, when simultaneously analysing samples from a representative MCL patient and cell line a significant correlation was observed between the NOXA/ MCL1 ratio and induction of apoptosis (Fig S10) , corroborating the hypothesis that the NOXA/MCL1 balance upon treatment is important for sensitivity to these drugs.
The efficacy of the combination of Dinaciclib and Orlistat was further validated in vivo in a mouse xenograft model of MCL. After 15 days of treatment, Orlistat alone led to reduced body weight and had a slight, not significant effect in reducing tumour growth. In contrast, Dinaciclib alone was well tolerated and displayed significant activity with a 56% reduction in tumour size, further corroborating its potential as monotherapy in MCL. Importantly, analogous to in vitro results, the most effective strategy was combined treatment of Dinaciclib with Orlistat achieving 80% regression of tumour volume (Fig 2C, upper panel) . Immunohistochemistry confirmed the decrease in MCL1 expression in Dinaciclib-treated tumours (Fig 2C, lower panel) .
This study demonstrates for the first time that, comparable to the observations in other haematological malignancies (Flynn et al, 2015) , Dinaciclib alone is effective in MCL in vitro and in vivo and may be an interesting compound for testing in clinical trials and a promising alternative to the CDK inhibitor Flavopiridol, which revealed only moderate effects in clinical studies (Jones et al, 2014) . The cytotoxic effect of Dinaciclib is dependent on reduction of MCL1 and can significantly be augmented by forced stabilization of NOXA achieved via co-treatment with FASNi. This promising dual targeting approach highlights the crucial role of the NOXA/MCL1 balance in MCL to determine cell fate and indicates that its pharmacological modulation is an effective strategy for treatment of MCL. This may be of special interest in patients resistant to bortezomib, as Orlistat stabilizes NOXA protein via interference with the ubiquitination process. After 24 h, induction of cell death was assessed by flow cytometry of AnnexinV/PI-labelled cells (upper panel; n = 7; bars represent the mean AE SD, *P < 0Á05). Protein expression levels of NOXA and MCL1 were determined 6 h after treatment with Western Blot and quantified using the ImageGauge Software (lower panel). (C) Dinaciclib displays significant activity as a monotherapy of MCL in a xenograft mouse model, which can be enhanced by addition of Orlistat. Upper panel: mice were inoculated subcutaneously into the right flank with 1:1 of 8 9 10 6 JEKO1 cells. Dinaciclib (25 mg/kg) or vehicle was administered intraperitoneally twice weekly. Orlistat (240 mg/kg) or vehicle was administered intraperitoneally once a week. The shortest and longest diameter of the tumour were measured with external calipers twice a week and tumour volumes were estimated using the following formula: (shortest diameter) 2 9 (longest diameter) 9 0Á5 (n = 6; in the Orlistat and combination group two mice died or were sacrificed due to marked weight loss; bars represent the mean AE SD *P < 0Á05; **P < 0Á01). Lower panel: decreased MCL1 expression in Dinaciclib-treated tumours. Harvested tumours were formalin-fixed before paraffin embedding on silane-coated slides. Immunohistochemical staining studies of MCL1 were evaluated with an LCN400 Scanner (Leica, Wetzlar, Germany) by means of 209 and 409 objectives. 
Authorship contributions

Conflict of interest
The authors declare no competing financial interests.
Supporting Information
Additional Supporting Information may be found in the online version of this article:
Data S1. Materials and methods. Although less pronounced as compared with Orlistat, the second FASNi Cerulenin accumulates NOXA, but has no effect on MCL1 protein. Nonetheless, Dinaciclib shifts the NOXA/MCL1 ratio towards NOXA. Fig S9. The NOXA/MCL1 ratio upon co-treatment of cells with Bortezomib and Dinaciclib is not related to cell death. High concentrations of Bortezomib produce a pro-apoptotic MCL1 cleavage product that is reduced upon addition of Dinaciclib. Fig S10. Correlation of apoptosis induction with the NOXA/MCL1 ratio.
